Abstract
Anogenital warts (AGW) are a common manifestation of human papillomavirus (HPV) infection, primarily caused by strains 6 and 11. According to results, mucosal HPV is transmitted through sexual contact, with risk factors including immunodeficiency, such as Human Immunodeficiency Virus (HIV). Individuals with HIV experience a higher incidence of AGW due to impaired immune function that hinders HPV clearance. There is currently no specific antiviral therapy available for HPV, although several management options exist. However, some of these treatments may cause pain and discomfort. Glycyrrhizinic acid (GA) has demonstrated potential in managing HPV infection because of its antiviral properties and minimal side effects. Despite these promising results, GA is not yet recognized as a standard therapy for AGW. This case report describes the effectiveness of Glizigen(®) (topical GA) combined with Viusid(®) (oral GA) in managing genital warts in a 28-year-old homosexual male living with HIV. The patient, examined by a dermatologist at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia, presented with perianal warts that had developed over 3 months. According to the physical examination carried out, multiple flesh-colored papules were reported, while histopathological analysis showed koilocytes, and polymerase chain reaction (PCR) confirmed HPV types 6 and 11. The treatment process, carried out using topical and oral GA, was administered from August to October 2024. The improvement was reported only in smaller lesions, while larger ones persisted, leading to electrocautery scheduling. The limited response observed in this case might be influenced by the patient's low CD4+ count, which potentially affects HPV clearance. Factors such as age, number of sexual partners, circumcision status, HPV type, and anatomical location of the lesions may also have played a role.